Page last updated: 2024-08-17

thymidine and pasireotide

thymidine has been researched along with pasireotide in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Ciccarelli, E; Czirják, S; Gaia, D; Góth, MI; Grossman, AB; Hanson, MR; Hanzély, Z; Hubina, E; Jordan, S; Khalaf, S; Korbonits, M; Losa, M; Nagy, GM; Nanzer, AM; Papotti, M; Terreni, MR	1

Other Studies

1 other study(ies) available for thymidine and pasireotide

Article	Year
Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours. European journal of endocrinology, 2006, Volume: 155, Issue:2 Topics: Adenoma; Animals; Antineoplastic Agents, Hormonal; Cell Division; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p27; Down-Regulation; Extracellular Signal-Regulated MAP Kinases; Growth Hormone-Secreting Pituitary Adenoma; Humans; In Vitro Techniques; MAP Kinase Signaling System; Octreotide; Pituitary Gland; Pituitary Neoplasms; Prolactinoma; Rats; Somatostatin; Thymidine; Tritium; Up-Regulation	2006

Article

Year

Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours.

European journal of endocrinology, 2006, Volume: 155, Issue:2

Topics: Adenoma; Animals; Antineoplastic Agents, Hormonal; Cell Division; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p27; Down-Regulation; Extracellular Signal-Regulated MAP Kinases; Growth Hormone-Secreting Pituitary Adenoma; Humans; In Vitro Techniques; MAP Kinase Signaling System; Octreotide; Pituitary Gland; Pituitary Neoplasms; Prolactinoma; Rats; Somatostatin; Thymidine; Tritium; Up-Regulation

2006